Skip to main content

Table 2 Virologic Outcomes of EI-AED Compared to NEI-AED Subjects

From: Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study

  EI-AED
(N = 19)
NEI-AED
(N = 85)
OR (95% CI) or
Difference ± SE
Adjusted for Year of and VL at
HAART Initiation
OR (95% CI) or
Difference ± SE
First HAART/AED Overlap     
   Virologic failure 10/16 (62.5%) 20/75 (26.7%) 4.58 (1.47 - 14.25)
P = 0.009
4.67 (0.92 - 23.62)
P = 0.062
   Average VL during period (log10) 3.3 ± 1.3 (n = 19) 2.4 ± 1.2 (n = 84) 0.8 ± 0.3;
P = 0.006
0.2 ± 0.3;
P = 0.376
   VL <400 at 6 months 4/12 (33.3%) 50/70 (71.4%) 0.20 (0.05 - 0.74)
P = 0.016
0.35 (0.06 - 2.07)
P = 0.247
   VL <400 at 12 months 4/11 (36.4%) 42/56 (75.0%) 0.19 (0.05 - 0.75)
P = 0.018
0.17 (0.02 - 1.42)
p = 0.102
All HAART/AED Overlaps*     
   Virologic failure 19/30 (63.3%) 34/122 (27.9%) 4.29 (1.51 - 12.21)
P = 0.006
4.19 (1.54 - 11.44)
P = 0.005
   Average VL during period (log10) 3.3 ± 1.3 (n = 34) 2.5 ± 1.3 (n = 142) 0.9 ± 0.3
P = 0.005
0.7 ± 0.3
P = 0.007
   VL <400 at 6 months 8/28 (28.6%) 84/121 (69.4%) 0.17 (0.06 - 0.53)
P = 0.002
0.25 (0.07 - 0.86)
P = 0.028
   VL <400 at 12 months 9/23 (39.1%) 71/96 (74.0%) 0.21 (0.07 - 0.61)
P = 0.004
0.22 (0.06 - 0.75)
P = 0.016
  1. OR (odds ratio): Odds of virologic event for EI-AED cases versus odds for NEI-AED controls; VL, viral load (copies/mL); * Up to three intervals used per subject